Biotech: Page 79
-
Courtesy of Apellis Pharmaceuticals
Apellis eye drug succeeds in one key study, but falls short in its twin
Highly anticipated study results showed divergent outcomes for the biotech's therapy in treating a form of vision loss known as geographic atrophy. Even so, Apellis plans to soon ask for FDA approval.
By Ned Pagliarulo • Updated Sept. 10, 2021 -
Mario Tama via Getty Images
Jennifer Doudna-founded CRISPR biotech raises new cash to broaden drug development work
Originally formed as a diagnostics developer by Doudna and three other cofounders, Mammoth Biosciences has accelerated plans to make gene editing medicines.
By Shoshana Dubnow • Updated Sept. 10, 2021 -
Explore the Trendlineâž”
Spencer Platt via Getty Images
TrendlineEmerging biotech
New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.
By BioPharma Dive staff -
Courtesy of National Resilience; Business Wire
Moderna expands mRNA vaccine supply in deal with new biotech producer
The company has previously said it could make up to 3 billion vaccine doses in 2022, depending on how booster shots are authorized.
By Shoshana Dubnow • Sept. 8, 2021 -
Permission granted by Apple Tree Partners
Venture capital pours more money into RNA medicines with the launch of Replicate
The company, which focuses on self-replicating RNA, comes equipped with $40 million from Apple Tree Partners and a stamp of approval from the former research head at Biogen.
By Jacob Bell • Sept. 8, 2021 -
Roche bets big on off-the-shelf cancer cell therapy with Adaptimmune deal
Long a bystander in the race to develop so-called allogeneic treatments, the cancer drugmaking giant has joined the fray with a wide-ranging alliance that could be worth up to $3 billion.
By Jonathan Gardner • Sept. 7, 2021 -
Courtesy of BioMarin Pharmaceutical
FDA halts tests of BioMarin drug amid heightened focus on gene therapy safety
On the heels of a two-day FDA meeting in which experts debated the risks of gene therapy, the biotech said its early-stage PKU treatment was associated with cancer in mice.
By Ben Fidler • Sept. 7, 2021 -
National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
Hint of benefit in Alzheimer's drug study fuel stock surge for Swiss biotech
A once-failed drug being developed by AC Immune and Roche appeared to slow cognitive decline in a small trial. But other study goals were missed, muddying the seemingly positive result.
By Ned Pagliarulo • Aug. 31, 2021 -
Courtesy of Galapagos
Galapagos CEO to retire, though successor yet to be announced
Onno van de Stolpe co-founded Galapagos in 1999. Under his watch, the Belgian biotech secured its first approved drug and a landmark deal with Gilead, though it has since hit a series of setbacks.
By Jacob Bell • Aug. 31, 2021 -
Permission granted by Laronde
Moderna founder's next big play in RNA raises $440M
Just a few months out of stealth mode, Laronde and its "endless RNA" technology have caught the attention of well-known investors like Fidelity, T. Rowe Price Associates and Invus.
By Jacob Bell • Aug. 30, 2021 -
Elizabeth Regan/BioPharma Dive
BioMarin wins European approval to sell drug for dwarfism
The drugmaker is setting the price for Voxzogo high, at an annual price of around $300,000 per patient, although the company expects to make "material discounts" in the coming years.
By Ned Pagliarulo • Aug. 27, 2021 -
Courtesy of Gilead Sciences
Gilead wins reversal of $1.2B penalty in CAR-T patent case
A federal appeals court overturned an earlier verdict that had ruled Gilead's Kite Pharma unit infringed on a patent held by Bristol Myers Squibb.
By Ned Pagliarulo • Updated Aug. 26, 2021 -
Courtesy of Regeneron Pharmaceuticals
New data bolster Regeneron's plan to defend top-selling eye drug
Early results show a higher dose of the company's flagship drug Eylea appears as safe as the marketed version, a step forward in the company's plan to fight off emerging competition in the years ahead.
By Kristin Jensen • Aug. 25, 2021 -
Vertex, looking to broaden its gene editing abilities, asks a young biotech for help
A freshly inked agreement gives Vertex the right to use tools from Arbor Biotechnology to develop "ex vivo" cell therapies for diseases like Type 1 diabetes and sickle cell, among others.
By Jacob Bell • Aug. 24, 2021 -
Mario Tama via Getty Images
With new results, J&J's $1B gamble on a targeted inflammation drug faces long odds
Theravance, which agreed to co-develop a next-generation JAK inhibitor with J&J three years ago, said the experimental drug failed a mid-stage study in ulcerative colitis, leaving its future in doubt.
By Jonathan Gardner • Aug. 24, 2021 -
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
With new Fate data, same promise, questions surround 'natural killer' cell therapy
Though early results from two of the biotech's experimental lymphoma treatments have shown promise, it’s unclear whether they can match the potency and durability of T cell therapies.
By Ben Fidler • Aug. 20, 2021 -
Coherus, known for biosimilars, nears an immunotherapy battle with big pharma
New lung cancer results could make Coherus the next entrant in an ultra-competitive market dominated by pricey drugs like Merck's Keytruda.
By Ben Fidler • Aug. 19, 2021 -
Kena Betancur via Getty Images
Private equity dives deeper into biotech with nearly $2B Bain fundraise
Bain Capital's latest life sciences fund, its third, is another example of private equity's growing interest in drug development.
By Jacob Bell • Aug. 17, 2021 -
Merck wins approval for cancer drug acquired in 2019 biotech buyout
The FDA cleared Welireg, which Merck picked up in its $1 billion deal for Peloton Therapeutics, to treat tumors associated with a rare genetic disease.
By Ned Pagliarulo • Aug. 16, 2021 -
Permission granted by Biogen
VA leaves Aduhelm off coverage list, recommending against controversial Alzheimer's drug
The decision, which does provide for certain exceptions, is another bump in what's become a rocky market rollout for Biogen's medicine.
By Ned Pagliarulo • Updated Aug. 12, 2021 -
Sarah Silbiger via Getty Images
FDA rejects FibroGen's kidney drug in major blow to company
While the decision was expected after a negative advisory panel last month, it's a significant setback that could trigger cost-cutting at the biotech, which said it will discuss next steps with partner AstraZeneca.
By Kristin Jensen • Aug. 11, 2021 -
NIAID. (2019). "T Regulatory Cells" [Microscope image]. Retrieved from Flickr.
GentiBio raises $157M as cell therapy for immune diseases draw investor interest
The biotech company is working with regulatory T cells, an immune cell type that's become the focus of several newly launched drugmakers like Abata Therapeutics and Sonoma Biotherapeutics.
By Shoshana Dubnow • Aug. 11, 2021 -
Maddie Meyer via Getty Images
Eyeing future outbreaks, Moderna partners with Canadian government on vaccine plant
While Canada has already secured more COVID-19 vaccine doses than it needs, the factory to be built is geared toward combating future pandemics.
By Jonathan Gardner • Aug. 10, 2021 -
Bluebird to wind down business in Europe amid gene therapy struggles
Shares in the biotech sunk in value as the company also announced new safety concerns for one of its leading programs.
By Jacob Bell • Aug. 9, 2021 -
Permission granted by Seagen
SeaGen builds cancer drug pipeline with China biotech deal
The Seattle drugmaker will pay $200 million upfront to acquire a HER2-targeting antibody-drug conjugate from China's RemeGen, giving it a potential challenger to AstraZeneca's Enhertu.
By Ned Pagliarulo • Aug. 9, 2021 -
Startup EQRx to take drug price mission public through $1.8B SPAC deal
A merger with a blank-check company backed by Casdin Capital will greatly expand the resources available to EQRx, which aims to develop competitors to existing drugs and sell them at "radically lower" prices.
By Ned Pagliarulo • Aug. 6, 2021
Previous
